Conversations with Oncology Investigators Bridging the Gap between Research and Patient Care


HNCU117

Interview with Robert I Haddad, MD

Track 1: Case discussion: A 55-year-old man with squamous cell carcinoma of the tongue with extracapsular extension undergoes glossectomy and neck dissection followed by concurrent cisplatin and radiation therapy
Track 2: Effect of primary tumor location and HPV status on selection of up-front treatment modality in localized head and neck cancer
Track 3: Case discussion: A 67-year-old man with HPV-positive metastatic squamous cell carcinoma of the tonsil receives the EXTREME regimen of platinum/5-FU/cetuximab
Track 4: Ongoing trials of immune checkpoint inhibitors for the first-line treatment of metastatic head and neck cancer
Track 5: Toxicity of anti-PD-1/PD-L1 and anti-CTLA-4 combination therapy compared to standard chemotherapy for metastatic head and neck cancer
Track 6: Unique tolerability concerns for patients with metastatic head and neck cancer receiving immune checkpoint inhibitor therapy
Track 7: CheckMate 141: Results of a Phase III study of nivolumab versus investigator’s choice of single-agent methotrexate, docetaxel or cetuximab for patients with recurrent squamous cell carcinoma of the head and neck
Track 8: Response rate and potential predictors of response to anti-PD-1/PD-L1 inhibitors in advanced head and neck cancer
Track 9: Available data with pembrolizumab in advanced head and neck cancer and practical considerations influencing the selection of an anti-PD-1 antibody
Track 10: Ongoing studies of the anti-PD-L1 antibody durvalumab alone and in combination for patients with advanced head and neck cancer
Track 11: Use of cetuximab for head and neck cancer in the front-line metastatic setting and in later lines of therapy
Track 12: Investigational approaches combining anti-PD-1/PD-L1 antibodies with chemotherapy and/or radiation therapy and potential integration of immunotherapeutic agents into earlier lines of therapy
Track 13: Results of a pilot randomized trial evaluating the effect of acupuncture on chemoradiation therapy-related dysphagia in head and neck cancer
Track 14: Future directions and areas of ongoing interest in the treatment of head and neck cancer
Track 15: Overview of the thyroid cancer treatment landscape
Track 16: Case discussion: A 45-year-old man with metastatic papillary thyroid cancer and increasing shortness of breath who experienced a prolonged response and improvement of symptoms with lenvatinib
Track 17: Management of lenvatinib-related hypertension, fatigue and weight loss
Track 18: Effect of sorafenib-related hand-foot syndrome on quality of life for patients receiving long-term treatment for thyroid cancer
Track 19: Ongoing research interest in combining VEGF tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors for patients with anaplastic and poorly differentiated thyroid cancer
Track 20: Sequencing of treatments for metastatic thyroid cancer
Track 21: Case discussion: A 55-year-old woman with medullary thyroid cancer, bone and liver metastases and rising CEA and calcitonin experiences an ongoing response to vandetanib
Track 22: Efficacy and side-effect profiles of the TKIs vandetanib and cabozantinib in advanced medullary thyroid cancer

Interview with Francis Paul Worden, MD

Track 1: Importance of the multidisciplinary team in preserving the overall well-being of patients undergoing curative treatment for local or locally advanced head and neck cancer
Track 2: Unique psychosocial considerations for patients with head and neck cancer
Track 3: Case discussion: A 52-year-old man with p16-positive locally advanced oral pharynx cancer and renal dysfunction who is not eligible for treatment with a platinum agent receives cetuximab and radiation therapy
Track 4: Ongoing Phase III RTOG-1016 trial of radiation therapy and cetuximab versus chemoradiation therapy in HPV-associated oropharynx cancer
Track 5: Efficacy and side-effect profile of cetuximab/radiation therapy and management of cetuximab-associated dermatologic toxicity
Track 6: Review of ERBB2 family inhibitors in the treatment of head and neck cancer
Track 7: Case discussion: A 63-year-old man with squamous cell carcinoma of the tonsil presents with dermal and lung metastases and experiences a complete clinical response to treatment with nivolumab
Track 8: Approved and investigational use of immune checkpoint inhibitor therapy, alone and in combination, in the treatment of head and neck cancer
Track 9: Effect of HPV and smoking status on treatment benefit with immune checkpoint inhibitors
Track 10: Perspective on the effect of radiation therapy on the tumor microenvironment
Track 11: Response rate and potential predictors of response with immune checkpoint inhibitor therapy
Track 12: Efficacy and tolerability data leading to the approvals of sorafenib and lenvatinib in radioiodine-refractory thyroid cancer
Track 13: Case discussion: A man with a large tracheal mass who experienced a sustained response to lenvatinib
Track 14: Ongoing investigations in thyroid cancer management
Track 15: Factors affecting the sequencing of therapy for metastatic thyroid cancer, including the role of observation in select patients
Track 16: Therapeutic options for patients with metastatic thyroid cancer after disease progression on lenvatinib and sorafenib
Track 17: Medullary and anaplastic thyroid cancer treatment landscape
Track 18: Case discussion: A man with HPV-positive metastatic squamous cell cancer of the tonsil who underwent local therapy for an isolated lung and liver metastasis and is currently free of disease
Track 19: Benefits of individualized bioselection treatment methods in patients with advanced laryngeal cancer
 
FACULTY:
 
Robert I Haddad, MD
Disease Center Leader
Center for Head and Neck Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Francis Paul Worden, MD
Associate Professor
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida